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1. Introduction
The Editorial Board of the Medicinal Chemistry section of the journal Molecules publishes here
its first Editorial, which has been prepared by highlighting, in sub-editorials of about one hundred
words, some selected recently published articles that may have a profound impact on drug discovery
and therapy.
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In particular, this editorial highlights new drug targets and mechanisms of action and new classes
of drugs, as well as new therapeutic uses for known drugs or the involvement of known biological
targets in new diseases. We also discuss some structural biology studies and new computational tools
that may pave the way for the rational design or identification of more efficacious and safer drugs.
Overall, the findings reported in these highlighted papers raise our hopes for the management of
difficult-to-treat diseases that are posing a growing health threat, with new or repurposed drugs that
overcome the limitations of currently applied therapies.
2. Hitting the Protozoan Parasite Proteasome: A New Avenue for Antimalarial and
Antitrypanosomatid Drug Discovery
Highlight by Diego Muñoz-Torrero
Protozoan diseases cause immense human suffering and death. Available drugs have a number of
drawbacks that make necessary the search for alternative antiprotozoal agents that hit novel parasite
targets. Two independent reports have shown that proteasome inhibition can derive potent and
selective compounds against major protozoan diseases. On the basis of the specificity profiles of
Plasmodium falciparum and human proteasomes and structural studies, Li et al. rationally designed
a peptidic inhibitor of the parasite proteasome, which has shown efficacy and good tolerability in a
Plasmodium infection mouse model [1]. After the phenotypic screen of 3 million compounds against
Leishmania donovani, Trypanosoma cruzi, and Trypanosoma brucei and hit-to-lead optimization, Khare et al.
identified (i) a lead compound that has shown compelling efficacy in mouse models of visceral and
cutaneous leishmaniasis, Chagas disease, and human African trypanosomiasis and (ii) the parasites’
proteasome as the pan-kinetoplastid target of this class of compounds [2]. Let’s keep our fingers
crossed that proteasome inhibitors will be soon combating malaria and trypanosomatid diseases!
3. Sulfonamidoacetamides: A Novel Treatment Strategy for Axon Regeneration?
Highlight by Arduino A. Mangoni
New drugs that effectively stimulate axon growth are urgently required as an increasing
number of patients suffer from the sequelae of neurological insults. After screening the
chemical libraries of ~170,000 synthetic small molecules, Ku et al. identified a set of compounds
with a common chemical scaffold containing a core substructure of sulfonamidoacetamide,
stimulating neurite outgrowth in P19 embryonic carcinoma cells and rat primary hippocampal
neurons [3]. Structure-activity guided optimization resulted in the identification of compound 2-(N-
(2-methoxyphenyl)-4-methylphenylsulfonamido)-N-(4-methoxypyridin-3-yl)acetamide, characterized
by relatively high metabolic stability and significant effects on axon growth both in retinal neuronal cells
and in an animal model of optic nerve injury [3]. Pending further pharmacodynamic/pharmacokinetic
characterization and optimization, this study might pave the way for the development of a new class
of drugs stimulating axon regeneration.
4. New Hope against Growing Threat of Antibiotic Resistance
Highlight by Catherine Guillou
The modulation of bacterial communication (Quorum Sensing, QS) to potentiate the effect
of existing antimicrobial drugs is a promising alternative to the development of new antibiotics.
Staphylococcus aureus is an important causative agent of acute and chronic bacterial infections in humans
as well as in animals. In addition, S. aureus often reside within the biofilm at the site of infection,
displaying enhanced resistance to antibiotics. Hamamelitannin (HAM), a natural product, was shown
to potentiate the effects of antimicrobials against S. aureus by interfering with QS. HAM affects S. aureus
biofilm susceptibility through the trapP receptor by affecting cell wall synthesis and extracellular
DNA release of S. aureus. Furthermore, this compound increases the susceptibility of S. aureus biofilm
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towards different classes of antibiotics in vitro and in vivo [4]. An analogue of HAM was found to be
more potent than HAM [5].
5. Targeting the Protein-RNA Complexes: A New Opportunity for Medicinal Chemists
Highlight by Simona Collina
RNA-protein interactions are of pivotal importance in the regulation of biological systems and are
implicated in gene expression defects. RNAs in cells are in complex with proteins called RNA-binding
proteins (RBPs), which influence every aspect of the biogenesis and function of RNAs. In their recent
paper, Hall and coworkers showed the potential of the complex formed by Lin28 (RBP) and let-7 (RNA),
as a new target for selected cancers; they furthermore discovered an antagonist of Lin28. Much can be
learned from this report, including the drug target potential of other RBP:RNA complexes involved in
pathophysiological mechanisms. This pioneering paper suggests a fascinating route for discovering
new drugs able to inhibit or enhance gene expression [6].
6. Repurposing Pentamidine: A New Hope for the Treatment of Gram-Negative Infections
Highlight by Jean Jacques Vanden Eynde
Pentamidine, 4,4’-[1,5-pentanediylbis(oxy)]dibenzenecarboximidamide, is a bisbenzamidine
in clinical use for the treatment of Human African trypanosomiasis, visceral leishmaniasis,
and Pneumocystis jiroveci pneumonia. Its activity is typically correlated to a strong affinity for the DNA
minor groove, but other intracellular targets have also been discovered [7]. The research group of E.D.
Brown [8] established that pentamidine was able to perturb the outer membrane of Gram-negative
pathogens through association with lipopolysaccharides and, in this case, without internal interaction.
Starting from that result, the study demonstrated that the diamidine could effectively act, in vitro, as a
potent adjuvant to enhance the sensitivity of polymyxin-resistant bacteria to Gram-positive antibiotics
such as rifampicin, erythromycin, and novobiocin. In vivo, a promising dose-sparing effect has been
observed when a combination of pentamidine and novobiocin was used for the treatment of systemic
Acinetobacter baumannii infections in mice. A novel potential use for pentamidine!
7. Fragment-Based Screening in Human Cells
Highlighted by Jarkko Rautio
A collaborative effort from the Scripps Research Institute, the University of Lausanne,
Bristol-Myers Squibb and the Salk Institute ingeniously demonstrates a chemical proteomic platform to
map small-molecule fragment-protein interactions directly in human cells. Typically, fragment-based
ligand and drug discovery (FBLD) emphasizes the identification of structurally simple hit compounds
by screening ~103 low-molecular weight compounds (<300 Da) at high concentrations (>100 µM) in
in vitro assays only with purified proteins. The group used the photoaffinity/click-label combination
to discover more than 2000 fragment–binding proteins in HEK293T cells, only a few of which are found
in DrugBank database. Using the quantitative MS-based SILAC (stable isotope labeling with amino
acids in cell culture) technique, they quantified and identified labeled proteins and tracked down
poorly characterized transmembrane protein PGRMC2 (progesterone receptor membrane component
2) for which selective ligands were previously lacking. This is an excellent article for those into
early-stage drug discovery and medicinal chemistry in general, and it likely paves the way to a huge
amount of useful research in the future [9].
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8. The Atomic Level Mechanism of LSD Action Has Been Solved
Highlight by György M. Keseru˝
The research group of Bryan L. Roth at the University of North Carolina, USA published the
high-resolution X-ray structure of Lysergic acid diethylamide (LSD) bound to serotonin 2B receptor,
one of its in-cell brain targets [10]. This study revealed for the first time how LSD is captured by its
receptor and described the conformational change at the binding site that closes the drug to the pocket
like a lid. This binding mechanism was connected to the long residence time of LSD that is responsible
for its long duration of action. This kind of interaction seems to be specific for LSD, since other
compounds such as the vasoconstrictor drug ergotamine might leave the binding site of the serotonin
2B receptor more open [11]. Structural data also help elucidate the activation of the receptor. It has
been demonstrated that LSD activates both the G-protein dependent and the G-protein independent
β-arrestin signalling pathways. Interestingly the team found that increasing the mobility of the lid
by introducing mutation L209A not only facilitated the unbinding of the drug, but more importantly
decreased β-arrestin2 recruitment significantly. Considering the option for functionally selective drugs
with preference for specific signalling pathways, the new crystal structure of the LSD-serotonin 2B
receptor complex could help in designing safer psychiatric drugs with less side effects.
9. PIM-1 Inhibition as a Novel Therapeutic Strategy for Alzheimer’s Disease
Highlighted by Christopher Hulme
Targeting Central Nervous System (CNS) kinases with small molecule inhibitors to deliver
therapeutics for neurodegeneration has so far proved elusive. An article by Oddo et al. [12] revealed
new utility for PIM-1 kinase, outside the oncology realm, to address Alzheimer’s disease. A selective
brain penetrable PIM-1 inhibitor, (3-cyano-4-phenyl-6-(3-bromo-6-hydroxy)phenyl-2(1H)-pyridone),
was evaluated in 3xTg-AD mice, demonstrating significant reductions in both Aβ and tau pathology
with improvements in cognitive deficits. At the heart of this effect is a proposed reduction of mTOR
activity, mediated by the inhibition of PIM-1-driven PRAS40 phosphorylation. With several PIM-1
inhibitors in trials, opportunities to rapidly realign efforts toward AD can now be exploited.
10. Tubulin-Bound Conformation of a Hypermodified Epothilone Analog
Highlight by Kelly Chibale
One approach to natural product-based medicinal chemistry is the development of synthetic
technologies to facilitate the synthesis of new analogues for structure-activity relationship (SAR) studies.
Karl-Heinz Altmann and his team [13] used ring-closing olefin metathesis as a key synthetic technology
to prepare 12-aza-epothilones (also known as azathilones). Highly potent inhibitors of cancer cell
growth in vitro were obtained, and meaningful SARs were delineated. Furthermore, the authors
determined the conformation of a representative azathilone bound to the target tubulin heterodimers,
which was found to be similar to that of the natural epothilones A and B. Although the bound
conformation did not provide a molecular basis for the observed SAR, it provided an opportunity for
further investigations aimed at gaining insight into target binding for this class of epothilone analogues.
11. Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict
Protein-Ligand Residence Time
Highlighted by F. Javier Luque
The concept of residence time is gaining increasing impact in drug discovery, because the lifetime
of drug occupancy is a key property for its pharmacological activity. However, its computation
poses a serious challenge due to the high demands in computer time required for the sampling
of drug unbinding, thus limiting practical industrial applications. In an effort to solve this
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question, Mollica et al. [14] reported an efficient computational approach that relies on simulating
the target-ligand unbinding by using molecular dynamics under scaled potential energy conditions.
This strategy facilitates the rupture of key intermolecular interactions, leading to unbinding events
in much shorter simulation times. After a fine-tuning of the computational protocol, the results
obtained for a series of glucokinase activators demonstrated that the calculated residence times were in
agreement with the experimental data. Albeit extension to a larger number of target-ligand complexes
is needed, the results support the potential of this technique for drug binding kinetics studies.
12. Natural Products as Sources of New Drugs from 1981 to 2014
Highlight by Rafik Karaman
In this study, David J. Newman’s group comprehensively updated and broadened the data on
the sources of new drugs which have been published in four different reviews during 1997–2012 [15].
Based on the new data covering the 34 years from 1 January 1981 to 31 December 2014, the group
has concluded that natural products are the stepping stone in the discovery and development of
drugs for the treatment of human diseases such as cancer, infectious (viral, microbial, and parasitic),
antidiabetic, inflammation and hypertension treatments. Furthermore, the data demonstrated that
the ideal solution to the current huge crisis facing the drug discovery and development sector can
be achieved by a multidisciplinary approach, consisting of both novel molecular diversity generated
from natural product sources and combinatorial synthetic procedures that rely on the manipulation of
biosynthetic routes.
13. Proteasome Subunit Selective Activity-Based Probes
Highlight by Michael Gütschow
Fifteen different types of core particles can exist in cells expressing all subunits of the constitutive
(cCP) and immunoproteasome (iCP). To study the proteasome assemblies, Herman S. Overkleeft’s
group at the Leiden Institute of Chemistry has designed and employed a panel of subtype selective,
peptidomimetic epoxyketone- or vinyl sulfone-based probes equipped with either BOPIPY(FL) or
Cy5 fluorophores as FRET pairs and targeting the caspase-, trypsin- or chymotrypsin-like activities
of proteasomes [16]. Cell extracts were treated with purposeful combinations of these FRET
donor/acceptor activity-based probes (ABPs) and resolved on native-PAGE. The intraproteasomal
FRET was analyzed by in-gel fluorescence measurements. For example, when a donor ABP is bound to
a cCP subunit and an acceptor ABP to an iCP subunit, or vice versa, which are assembled in the same
core particle, mixed proteasomes can be detected. Asymmetric mixed proteasomes were analytically
accessible as well. Moreover, the authors identified the predominantly produced proteasome types
in HeLa cells, exposed to interferon-γ. Thus, a novel, sensitive and straightforward assay to identify
proteasome core particle composition was introduced.
14. An Effective CADD Method for the Discovery and Rational Design of Natural
Product Derivatives
Highlighted by Hong Liu
DPP-4 inhibitors are considered a promising class of antidiabetic drugs. In particular, long-acting
DPP-4 inhibitors are clinically needed for improving patients’ compliance with a safe, once daily
or weekly dosing regimen. Li et al. [17] identified the natural product isodaphnetin to be a potent
DPP-4 inhibitor (IC50 = 14 µM) through target fishing dock (TarFisDock). Utilizing highly efficient 3D
molecular similarity-based scaffold hopping as well as electrostatic complementary methods, Li et al.
discovered a series of novel 2-phenyl-3,4-dihydro-2H-benzo[f ]-chromen-3-amine derivatives with
highly potent DPP-4 inhibitory activities. The most potent inhibitor of this series exhibited an IC50
value of 2.0 nM, an approximately 7400-fold improvement of potency compared with isodaphnetin,
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which also displayed good oral bioavailability (F = 89%). In addition, this compound presented over
80% inhibition of DPP-4 at 3 mg/kg oral dose in 24 h, which is better than that of the long-acting
positive control, omarigliptin. Moreover, this compound also improved the glucose tolerance at
a comparable level with omarigliptin. In this study, an effective CADD method (TarFisDock) and
medicinal chemistry strategies were successfully implemented to discover a promising DPP-4 inhibitor
from a natural product, with therapeutic potential as a long acting antidiabetic agent [17].
15. New 1,4-Dihydropyridines as Sirt1 Activators as Potential Treatment for
Dysmetabolic Syndrome
Highlighted by Rino Ragno
Recently, Valente et al. [18] disclosed a series of 1,4-dihydropyridines (DHPs) displaying SIRT1
activation capability and high nitric oxide release in HaCat cells, which ameliorated skin repair in a
mouse model of wound healing. In addition, DHPs derivatives showed to improve mitochondrial
activity. The observed biological effects were impaired by co-administration of the AMPK inhibitor
compound C or of the SIRT1 inhibitor EX-527, proving that the DHPs mechanism of action involves
the SIRT1/AMPK pathway. Moreover, when tested in several cancer cell lines, water soluble
DHP compounds displayed antiproliferative effects and increased H4K16 histone deacetylation.
These findings will be of great utility to elucidate SIRT1 biological functions, such as its role in
dysmetabolic syndrome and cancer.
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